Form 4: Pfizer Director Ronald Blaylock Acquires Phantom Stock

Pfizer Inc. director Ronald E. Blaylock was granted 7,686.539 phantom stock units as part of deferred director compensation.

Summary

• Director Ronald E. Blaylock acquired 7,686.539 phantom stock units on April 23, 2026.
• The units were granted under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors.
• Each phantom unit represents one share of common stock, valued at $26.67 per unit.
• The total beneficial ownership following this transaction is 84,012.66 units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding standard director compensation, having no material impact on the company's financial outlook.

Positives

• Director alignment with company performance through equity-based compensation.
• Standard deferred compensation practice for non-employee directors.

Negatives

• None identified.

Risks

• Value of phantom stock units is subject to the future market performance of Pfizer common stock.

Future Outlook

The units are settled in cash or common stock at the director's election following their retirement from the Board of Directors.

Industry Context

StockSavvy.ai notes that this is a routine disclosure of director compensation, common among large-cap pharmaceutical companies to ensure board members maintain a long-term interest in shareholder value.

Comparison to Industry Standards

• The use of phantom stock units for director compensation is a standard governance practice among S&P 500 companies.
• The structure aligns with compensation models used by peers such as Merck and Bristol Myers Squibb.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal impact; reflects standard board compensation practices.

Next Steps

• The units will be held until the director's retirement from the Board.

Key Dates

Keywords

Pfizer, PFE, Form 4, Director Compensation, Insider Trading, Phantom Stock